| 摘要 |
The invention relates to the treatment of mammalian diseases manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of histone deacetylases 1, 2 and/or 3 (HDACs 1-3), as well as isotype-selective inhibitors of HDAC1 and/or HDAC2, to potentiate therapeutic activity of microtubule-stabilization agents.
|
